Inhibition of alveolar bone loss in beagles with the NSAID naproxen.
The non-steroidal anti-inflammatory drug(NSAID) naproxen was studied in 11 beagle dogs over a 13-month period to determine its effect on the progression of periodontitis. Following a 6-month pretreatment period, 5 dogs received naproxen daily at a dosage of 2.0 mg/kg for 1 month, then 0.2 mg/kg for 6 months. Six control dogs received a gelatin capsule daily as placebo. Standardized radiographs were used to measure the rate of bone loss during the pretreatment and treatment periods. In the control dogs, the rate of bone loss was seen to increase during the treatment period although the increase was not statistically significant. In dogs treated daily with naproxen, the rate of bone loss in the treatment period was significantly less at 4 months of treatment; however, at 7 months the difference, though lower than pretreatment rate, was not significant. When the percent change in rate of bone loss during the overall 7-month treatment period was compared with pretreatment rate, the control dogs demonstrated a 38% increase in rate of bone loss during the treatment period contrasting with a 61% decrease in bone loss rate in naproxen-treated dogs. The data indicate that the non-steroidal anti-inflammatory drug naproxen can significantly inhibit alveolar bone loss in beagles. At 4 months of treatment the rate of bone loss in the naproxen-treated dogs was significantly less than pretreatment, but at 7 months of treatment the rate was no longer statistically significantly less than baseline. This probably reflects a dose response to naproxen treatment for, after 30 days of the treatment period, the naproxen dosage was reduced 10-fold due to tolerance by the beagle.
Howell
T H
TH
Department of Periodontology, Harvard School of Dental Medicine, Boston, MA.
Jeffcoat
M K
MK
Goldhaber
P
P
Reddy
M S
MS
Kaplan
M L
ML
Johnson
H G
HG
Hall
C M
CM
Williams
R C
RC
D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000517:prevention & control*; D000818:Animals; D016009:Chi-Square Distribution; D004285:Dogs; D005260:Female; D008137:Longitudinal Studies; D008336:Mandibular Diseases; D008439:Maxillary Diseases; D009288:Naproxen / Q000627:therapeutic use*; D010518:Periodontitis / Q000188:drug therapy / Q000517:prevention & control*
D009288:Naproxen